Celularity Inc. Class A (CELU) Peer Comparison
$0.80
$-0.05
(-5.79%)
As on 30-Oct-2026 16:00EST
Market cap
$26 Mln
Revenue (TTM)
$17 Mln
P/E Ratio
--
P/B Ratio
9.9
Div. Yield
0 %
Edit
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
26 | 16,932 | 10,811 | 5,010 | 4,522 |
Revenue ($ Mln) |
17 | 2,497 | 102 | 1,156 | 497 |
Net Profit ($ Mln) |
-47.14 | 885.14 | -349.47 | -105.97 | 128.63 |
Net Margin (%) |
-269.61 | 35.45 | -341.87 | -9.17 | 25.86 |
RoE (%) |
-- | 46.96 | -22.16 | -- | 32.94 |
Price to Earnings |
-- | 20.78 | -- | -- | 42.02 |
Price-To-Book |
9.89 | 9.23 | 6.49 | 1,743.27 | 9.83 |
Income Statement ($ Mln)
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
17.49 | 2,496.86 | 102.23 | 1,155.55 | 497.40 |
|
Cost of Revenue
|
18.55 | 93.32 | -74.16 | 87.91 | 144.39 |
|
Gross Profit
|
6.48 | 2,236.43 | 39.20 | 1,658.90 | 256.57 |
|
Operating Expenses
|
64.80 | 1,400.14 | 583.29 | 929.29 | 348.88 |
|
Operating Profit (EBIT)
|
-58.49 | 1,003.39 | -404.89 | 138.35 | 4.13 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-47.14 | 1,065.84 | -349.70 | -85.09 | 124.22 |
|
Provision for Tax
|
0.00 | 180.70 | 0.00 | 20.88 | -4.41 |
|
Profit after Tax (Net Income)
|
-47.14 | 885.14 | -349.47 | -105.97 | 128.63 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-35.53 | 1,833.83 | 1,614.53 | -191.21 | 467.46 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
71.96 | 267.78 | 63.02 | 2,622.85 | 35.03 |
|
Current Liabilities
|
59.74 | 411.88 | 89.72 | 776.08 | 138.98 |
|
Total Liabilities
|
107.33 | 2,844.42 | 1,742.81 | 2,898.77 | 413.23 |
Assets ($ Mln)
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
89.72 | 1,191.87 | 768.68 | 669.93 | 320.16 |
|
Current Assets
|
6.45 | 1,321.62 | 998.59 | 2,537.78 | 321.30 |
|
Total Assets
|
107.33 | 2,844.42 | 1,742.81 | 2,898.77 | 413.23 |
|
Total Debt*
|
36.02 | 162.20 | 76.60 | 636.03 | 29.00 |
|
Net Current Assets
|
0.00 | 909.75 | 908.87 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-13.25 | 884.27 | -232.89 | 711.20 | 42.03 |
|
Cash Flow from Investing Activities
|
-- | 350.44 | -521.06 | -861.98 | 2.16 |
|
Cash from Financing Activities
|
18.65 | -969.59 | 990.71 | 331.09 | -93.39 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-227.83 | 32.82 | -24.09 | 35.24 | -5.80 |
|
ROE (%)
|
627.65 | 46.96 | -22.16 | -104.75 | 32.94 |
|
ROA (%)
|
-33.42 | 28.91 | -23.06 | -2.29 | 17.22 |
|
EBIT Margin (%)
|
-256.29 | 42.02 | -341.82 | 9.82 | 1.35 |
|
Net Margin (%)
|
-269.61 | 35.45 | -341.87 | -9.17 | 25.86 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-63.02 | 9.12 | 133.74 | -35.05 | 38.94 |
|
EBIT Growth (%)
|
31.20 | 23.13 | -18.50 | -87.09 | 121.67 |
|
Net Profit Growth (%)
|
36.45 | 30.57 | -18.42 | -114.10 | 111.69 |
|
EPS Growth (%)
|
43.41 | 38.78 | -2.42 | -116.63 | 133.38 |
|
Book Value Growth (%)
|
-58.77 | -7.57 | 48.81 | -28.11 | 46.83 |
Valuation Ratios
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.35 | 15.79 | -21.09 | 8.98 | -45.11 |
|
Price / Book Value
|
9.89 | 9.23 | 6.49 | 1,743.27 | 9.83 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
EV/EBITDA
|
-1.59 | 14.90 | -29.43 | 33.08 | 153.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-0.25 | 0.00 | 0.01 | -0.07 | 0.02 |
|
Current Ratio
|
0.11 | 3.21 | 11.13 | 3.27 | 2.31 |
|
Quick Ratio
|
0.10 | 3.14 | 11.13 | 3.13 | 2.25 |
|
Interest Coverage
|
-19.29 | -- | -1,279.94 | 0.57 | -- |
Operating Efficiency Ratios
| Celularity Inc. Class A (CELU) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.77 | 13.16 | 0.00 | 20.60 | 9.60 |
|
Asset Turnover
|
0.12 | 0.82 | 0.07 | 0.25 | 0.67 |
|
Receivable days
|
125.26 | 43.48 | 8.82 | 35.90 | 51.56 |
|
Inventory Days
|
54.40 | 96.17 | -- | 261.74 | 68.47 |
|
Payable days
|
452.31 | 147.97 | -- | 159.73 | 26.19 |
|
Cash Conversion Cycle
|
-272.65 | -8.32 | -- | 137.90 | 93.85 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
